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Background: Payments for red blood cell (RBC) transfusions are separate from US Medicare bundled payments for
dialysis-related services and medications. Our objective was to examine the economic burden for payers when
chronic dialysis patients receive outpatient RBC transfusions.
Methods: Using Truven Health MarketScanW data (1/1/02-10/31/10) in this retrospective micro-costing economic
analysis, we analyzed data from chronic dialysis patients who underwent at least 1 outpatient RBC transfusion who
had at least 6 months of continuous enrollment prior to initial dialysis claim and at least 30 days post-transfusion
follow-up. A conceptual model of transfusion-associated resource use based on current literature was employed to
estimate outpatient RBC transfusion payments. Total payments per RBC transfusion episode included screening/
monitoring (within 3 days), blood acquisition/administration (within 2 days), and associated complications
(within 3 days for acute events; up to 45 days for chronic events).
Results: A total of 3283 patient transfusion episodes were included; 56.4% were men and 40.9% had Medicare
supplemental insurance. Mean (standard deviation [SD]) age was 60.9 (15.0) years, and mean Charlson comorbidity
index was 4.3 (2.5). During a mean (SD) follow-up of 495 (474) days, patients had a mean of 2.2 (3.8) outpatient RBC
transfusion episodes. Mean/median (SD) total payment per RBC transfusion episode was $854/$427 ($2,060) with
72.1% attributable to blood acquisition and administration payments. Complication payments ranged from mean
(SD) $213 ($168) for delayed hemolytic transfusion reaction to $19,466 ($15,424) for congestive heart failure.
Conclusions: Payments for outpatient RBC transfusion episodes were driven by blood acquisition and
administration payments. While infrequent, transfusion complications increased payments substantially when they
occurred.
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Anemia is common in end-stage renal disease (ESRD) and
results from reduction of erythropoietin production [1].
Prior to the development of pharmacologic treatments
for anemia, red blood cell (RBC) transfusions were the
mainstay of anemia treatment, and approximately 55% to
60% of dialysis patients received RBC transfusions to avoid
severe anemia [2,3]. RBC transfusions are associated with
a variety of complications, including hemolytic and non-
hemolytic transfusion reactions, infections, transfusion-
related acute lung injury (TRALI), transfusion-associated* Correspondence: mgitlin@amgen.com
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reproduction in any medium, provided the orcirculatory overload (TACO), and hyperkalemia [3-10].
In 2009, the rate of RBC transfusion-associated adverse
reactions across all disease states was reported as
approximately 0.25% [11]. However, the rates of RBC
transfusion-related complications may be higher among
chronic dialysis patients because of their significant
comorbid disease severity and concerns about patients’
fluid overload. Furthermore, while the overall rates of
these complications may be low, their outcomes can be
severe (hospitalization or death) and their associated
costs are high [12-14].
The use of RBC transfusion as a treatment for anemia
declined dramatically after the approval of the first
erythropoiesis-stimulating agent (ESA) in 1989 [15,16].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Gitlin et al. BMC Nephrology 2012, 13:145 Page 2 of 9
http://www.biomedcentral.com/1471-2369/13/145In the 1995 annual report of the United States Renal
Data System (USRDS), the reported rate of outpatient
RBC transfusion in hemodialysis patients dropped from
16% in 1989 to 2% by 1993 [17]. The overall rate of RBC
transfusions (per 1000 patient-years) in the hemodialysis
setting decreased by about half from 535.33 in 1992 to
263.65 in 2005 [16]. About 83% to 94% of chronic dialysis
patients now use an ESA to treat chronic anemia [18].
With the newly implemented Medicare Prospective Pay-
ment System (PPS) for ESRD patients, reimbursement to
providers is capitated to include dialysis and separately
billable medications and services (ie, ESAs, iron, dialysis
supplies, lab tests) but does not include blood and blood
products. Since RBC transfusion use in ESRD patients on
dialysis could potentially increase, it is important to
understand transfusion-associated payments and out-
comes in this patient population.
Incomplete accounting of payments related to RBC
transfusion administration may provide misleading infor-
mation to policy makers determining reimbursement
policy in a healthcare system such as Medicare. The pur-
pose of this retrospective claims analysis study was to
use a micro-costing approach to examine the economic
burden for payers when chronic dialysis patients receive
outpatient RBC transfusions. This study will assist in
quantifying the economic impact to payers of RBC
transfusions as they are tracked within many of the PPS
surveillance programs and will inform future studies
examining RBC transfusion and associated payments in
Medicare claims data.Methods
Data sources
The Truven Health MarketScanW Commercial Claims
and Encounter and Medicare Supplemental and Coord-
ination of Benefits Databases were used for this study.
These databases are constructed from privately insured
paid medical and prescription drug claims. The Market-
Scan Commercial Database contains the inpatient, out-
patient, and outpatient prescription drug experience of
approximately 30 million employees and their depen-
dents (in 2010) covered under a variety of fee-for-service
plans, managed care health plans, and indemnity plans.
In addition, the MarketScan Medicare Database contains
the healthcare experience of approximately 3.42 million
retirees (in 2010) with Medicare supplemental insurance
paid for by employers. Medicare-covered portion of
payment, employer-paid portion, and patient-paid por-
tion are included in this database. The MarketScan
Commercial and Medicare Databases provide detailed
cost, use, and outcomes data for healthcare services per-
formed in both inpatient and outpatient settings. The
medical claims are linked to outpatient prescription-drug claims and person-level enrollment data through
the use of unique enrollee identifiers. All personal iden-
tifiers were removed.Transfusion episode inclusion criteria
All analyses in this study were performed at the level
of the transfusion episode. Eligible patients were first
identified using the following criteria: inclusion in the
MarketScan Commercial or Medicare Databases with
≥ 2 claims (to ensure that they were treated for chronic
disease) for chronic dialysis ≥ 30 days apart and within
365 days between January 1, 2002, and October 31, 2010
(codes used to identify chronic dialysis claims are listed
in Additional file 1: Table S1); had ≥ 6 months of con-
tinuous enrollment prior to first chronic dialysis claim to
measure baseline clinical characteristics; had ≥ 1 out-
patient RBC blood transfusion on or after date of first
chronic dialysis claim through January 31, 2011 (codes
used to identify RBC blood transfusion claims are listed
in Additional file 1: Table S2); had no terminating
events (defined as end of continuous enrollment, end of
MarketScan data [January 31, 2011], death, or kidney
transplant) between first chronic dialysis claim and first
outpatient RBC transfusion; and had ≥ 30 days of con-
tinuous enrollment after the first RBC transfusion to iden-
tify and measure subsequent RBC transfusion-related
complications. RBC transfusions were identified using
revenue codes (UB-04), Current Procedural Terminology
(CPT), and Healthcare Common Procedure Coding Sys-
tem (HCPCS) codes (codes used to identify transfusion-
related complications claims are listed in Additional
file 1: Table S3).
RBC transfusion–related complications that could be
identified in the coded dataset and could be reasonably
attributed to a transfusion episode (based on medical
literature and expert clinical opinion) included febrile
non-hemolytic transfusion reaction, air embolism, or
phlebitis; acute hemolytic transfusion reaction; allergic
reaction; TRALI; TACO; delayed hemolytic transfusion
reaction; congestive heart failure (CHF); and hyperka-
lemia. To increase the likelihood that CHF or hyper-
kalemia complications were directly related to the RBC
transfusion episode (rather than a pre-existing condition
that coincided with the transfusion), patients with a his-
tory of CHF or hyperkalemia during the pre-index period
were excluded from the complication cost analyses (but
not from overall cost analysis). Because of the short
follow-up period post–transfusion episode, we could not
collect information on longer-term complications that
might require more time to develop or be diagnosed
(e.g., transfusion-related infections and iron overload).
A summary of the patient selection and transfusion epi-
sode time frame is presented in Figure 1.
Figure 1 Patient selection time frame.
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Demographic information was collected on the date of
the first chronic dialysis claim. Clinical characteristics
were measured during the 180 days prior to the first
chronic dialysis claim. Because some patients had multiple
RBC transfusion claims within a short time frame, we
combined individual claims within 3 days of each other
into a transfusion episode, which was the unit of obser-
vation for this study. Because pre- and post-transfusion
screening and monitoring payments could not be differ-
entiated for patients with more than 1 transfusion claim
within an episode, we combined screening and monitoringFigure 2 Transfusion episode time frame. Abbreviations: CHF, congestiv
transfusion-related acute lung injury.payments 3 days prior to and 3 days post–transfusion
episode. Blood acquisition and administration payments
were examined from transfusion episode date to 2 days
post–RBC transfusion episode.
With the exception of delayed hemolytic transfusion
reactions, all complications were identified up to 0 to
3 days post–RBC transfusion episode. Hemolytic trans-
fusion reactions were identified 4 to 45 days post–RBC
transfusion episode (Figure 2). If a claim for RBC
transfusion–related complication was linked to ≥ 1
RBC transfusion episode, it was linked to the earliest epi-
sode. If a claim for a complication could not be linked toe heart failure; TACO, transfusion-associated circulatory overload; TRALI,
Table 1 Demographic and clinical characteristics
Patients
N = 3,283a
Age, mean years (SD) 60.9 (15.0)
Sex, n male (%) 1,850 (56.4)
Geographic region, n (%)
Northeast 253 (7.7)







Deyo Charlson comorbidity index, mean score (SD) 4.32 (2.45)









Dialysis modality, n (%)
Hemodialysis 1,997 (60.8)
Peritoneal dialysis 207 (6.3)
Unknown 1,095 (33.4)
Transfusion episodes with ≥ 30 days
follow-up, mean number (SD)
2.15 (3.78)
Length of follow-up, mean days (SD) 494.76 (474.19)
aChronic dialysis patients with ≥ 1 outpatient red blood cell transfusion
episode.
CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease;
SD, standard deviation.
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windows, the claim was not included in the analyses.
Micro-costing/component analysis approach
We used a micro-costing approach to measure cost
based on the components of resource units and their
payment values [19-21]. We included payments for blood
acquisition, transfusion administration, RBC transfusion–
related lab tests, and transfusion complications [21].
For the base-case analysis, we calculated component
payments for (1) RBC transfusion screening and moni-
toring, (2) blood acquisition and administration, and
(3) transfusion-related complication, which were summed
to calculate (4) total payment for each RBC transfusion
episode.
We conducted subgroup analyses for (1) patients with
an acute bleed or surgery during the 180 days prior to
initial dialysis claim, (2) patients with cancer or blood
disease during the 180 days prior to initial dialysis claim,
and (3) patients who experienced an RBC transfusion-
related complication, by type of complication. We also
performed sensitivity analyses by excluding cost outliers
(RBC transfusion episodes with the top 1% of blood
acquisition and administration costs or those with costs
equal to $0 were excluded), varying the payment time
frames (using both a narrow and broad time window
[defined in Figure 2] in identifying and defining payment
claims to RBC transfusion episodes), and estimating
mean payment per unit of blood based on a blood acqui-
sition and administration claim analysis.
Results
Patient sample
From an initial sample of 105,260 patients with ≥ 2
chronic dialysis claims, we had a final sample of 3,283
chronic dialysis patients who met all of the selection
criteria. Requiring 6 months of pre-index data and ≥ 1
outpatient RBC transfusion contributed to the greatest
loss of subjects. Among the 3,283 chronic dialysis patients,
there were 7,049 outpatient RBC transfusion episodes
used in the micro-costing analyses. Mean (standard devi-
ation [SD]) patient follow-up was 494.76 (474.19) days.
Patient demographics and clinical characteristics
Patients’ demographic and clinical characteristics are
presented in Table 1. Mean (SD) age was 60.9 (15.0)
years, 56.4% of patients were men, and 40.9% of patients
had Medicare supplemental insurance. The three most
frequent comorbidities were hypertension (93.9%), dia-
betes (50.6%), and CHF (35.6%). Hemodialysis was per-
formed in 60.8% of patients, peritoneal dialysis in 6.3%,
and type of dialysis was unknown in 33.4%. Patients
experienced a mean 2.15 transfusion episodes during
the follow-up period. Transfusion was administered atoutpatient hospital facilities in 82.0%, ESRD facilities in
9.4%, hospital emergency rooms in 2.6%, and unknown
in 6%.
Red blood cell transfusion episode payments
The component and total payments for RBC blood
transfusion episodes are presented in Table 2. Mean
(SD) total payment per RBC transfusion episode was
$854 ($2,060). The median payment was $427 (25th
percentile, $53; 75th percentile, $1071), suggesting that
payments were not normally distributed. The largest
component (72.0%) of the total payment was blood ac-
quisition and administration (mean, $615; SD, $1,237;
median, $289). Pre- and post-transfusion screening and
monitoring component payments represented 22.6% of
the total payment (mean, $193; SD, $616; median, $34).
Table 2 Base-case payment per red blood cell transfusion episode
Payments and Events All patientsa (N= 3,283); All episodes (N = 7,049) Min Max
Mean SD Median 25th percentile 75th percentile
Average payment per episode
All payers
Transfusion screening/monitoring $193 $616 $34 $0 $189 $0 $22,673
Blood acquisition and administration $615 $1,237 $289 $11 $801 $0 $30,962
Transfusion complications $75 $1,317 $0 $0 $0 $0 $61,059
TOTAL screening, transfusion and
complication payments
$854 $2,060 $427 $53 $1,065 $0 $74,452
Number of services per episode
Transfusion screening/monitoring 2.87 2.93 2.00 0.09 5.00 0.00 20.00
Blood acquisition and administration 2.04 1.26 2.00 1.00 3.00 1.00 12.83
aPatients with ≥ 1 outpatient red blood cell transfusion.
SD, standard deviation.
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RBC transfusion episodes were relatively low (mean,
$75; SD, $1,317; median, $0) but individual episode pay-
ments ranged from mean (SD) $213 ($168) for delayed
hemolytic transfusion reaction to $19,466 ($15,424) for
CHF. When evaluating total payments by primary payer
type, the mean payments were similar. Mean payments
(median; SD) per RBC blood transfusion episode were
$855 ($388; $2,728) and $853 ($457; $1,428) for Medi-
care primary and commercial primary, respectively.
Subgroup analyses
We estimated per RBC transfusion episode payments for
3 subgroups (Figure 3). Screening and monitoring costs
varied minimally between patients with cancer or blood
disease; patients with an acute bleed or surgery; and
patients who did not have cancer, blood disease, acuteFigure 3 Red blood cell transfusion episode payments for patients wbleed, or surgery. However, there was significant vari-
ation in blood acquisition and administration payments.
Patients with cancer or blood disease had the highest
mean payment (mean, $737; SD, $1,502), followed by
patients with neither acute bleed nor cancer (mean,
$542; SD, $1,044). Mean total payment per RBC transfu-
sion episode was higher than base-case estimates (Table 2)
for patients with cancer or blood disease (mean, $969; SD,
$1,948) and lower than base-case estimates for patients
with an acute bleed or surgery (mean, $733; SD, $1,195).
Figure 4 summarizes payments made for various
types of transfusion-related complications. Payments
for CHF (mean, $19,466) and allergic reactions (mean,
$11,655) were the most expensive complication payments.
TACO (63 episodes) and hyperkalemia (51 episodes), were
the most commonly observed types of complications.
Among the RBC transfusion episodes associated withith history of acute bleed/surgery or cancer/blood diseases.
Figure 4 Mean red blood cell transfusion payments for patients with complications, by type of complication. Abbreviations: CHF,
congestive heart failure; TACO, transfusion-associated circulatory overload.
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events occurred on the same date as the RBC transfu-
sion start date.
Sensitivity analyses
We performed sensitivity analyses by excluding cost out-
liers, varying time frames (narrow- and broad-window
time frames) and reestimating the component and total
payments per RBC transfusion episode. As shown in
Table 3, relative to base-case estimates, screening and
monitoring component payments increased slightly when
outliers were excluded (mean, $214; SD, $451) and when
we used the broad-window time frame (mean, $225;Table 3 Sensitivity analysis of RBC transfusion episode paym





Total payment per RBC transfusion $854 (2,060)
RBC, red blood cell; SD, standard deviation.SD, $712) but decreased slightly when we used the
narrow-window time frame (mean, $172; SD, $598). Blood
acquisition and administration payments were higher
when outliers were excluded (mean, $696; SD, $701) but
similar to the base case estimates when narrowing and
broadening the time frame. When using the broad-
window time frame, complication payments greatly
increased from the base case’s mean (SD) of $75 ($1,317)
to a mean of $120 ($1,520). Total payment per RBC
transfusion episode was highest when cost outliers were
excluded (mean, $971; SD, $1,982) and when we used
the broad-window time frame (mean, $931; SD, $2,239)
compared to the base-case estimates.ents by time frame
and bottom $0 patients Narrow window Broad window
(N = 4,844) (N = 7,049) (N = 7,049)
$214 (451) $172 (598) $225 (712)
$696 (701) $615 (1,237) $615 (1,237)
$86 (1,541) $56 (1,149) $120 (1,521)
$971 (1,982) $814 (1,940) $931 (2,239)
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acquisition and administration unit. Per-unit data were
available for 340 outpatient RBC transfusion episodes.
When these episodes were analyzed, the transfusion
screening/monitoring mean (SD) payment was $245
($425), the blood acquisition and administration mean
payment was $433 ($495), and the mean payment for
transfusion complications was $153 ($1,915). Per-unit
total transfusion episode mean payment was $827
($2,127).
Discussion
We evaluated 3,283 chronic dialysis patients with at least
1 outpatient setting RBC transfusion episode. Most of
the patients had diabetes measured during the pre-index
period. In the base case, 72.1% of the total payments
were due to blood acquisition and administration, with
the remainder of payments attributable to screening and
monitoring and, to a lesser extent, transfusion-related
complications. Total RBC transfusion payments were
higher for patients with cancer or blood disease than
those with an acute bleed or in our base-case estimates.
Sensitivity analyses suggest that the base-case results
were robust. Total payment estimates increased when
both the top 1% most expensive episodes and $0 pay-
ment episodes were excluded. Payments became slightly
lower when a narrow-window time frame was used and
increased slightly with a broad-window time frame. The
variations in total payments among all sensitivity ana-
lyses were less than 15% different from the base-case
total payment estimates. Across all sensitivity analyses,
the blood acquisition and administration payments con-
sistently were the most expensive component payment.
Under the newly implemented Medicare PPS for ESRD
patients, reimbursement is capitated to include dialysis
and previously separately billable medications and ser-
vices. Payments for blood and blood products are not,
however, included in the new PPS bundle. As patients are
treated to a lower hemoglobin level, the resulting lower
hemoglobin levels could also create a medical necessity
for RBC transfusions. The use of transfusions to supple-
ment ESA therapy in ESRD patients on dialysis may
increase because of economic incentives and clinical
necessity. It is, therefore, important to comprehensively
examine the transfusion-associated payments made within
the chronic dialysis patient population in order to under-
stand the economic consequences of the recent changes
in reimbursement.
Our results differ somewhat from a recent cost analysis
that used an activity-based costing model of RBC trans-
fusions in a surgical population (based on observation of
real-life activities in four hospitals in the United States
and Europe) to identify the costs for each transfusion-
related task and resource [21]. Overall, total inpatientRBC transfusion costs were $522 to $1183 (mean, $761)
per unit across the four hospitals (a considerable por-
tion of the costs was related to pre-surgical testing for
blood type/screening in patients who never received a
transfusion) [21]. These results were similar but slightly
lower than our mean per-unit payment estimate of $827
(SD, $2,127). Blood acquisition costs in the other study
were only 21% to 32% ($154 to $248 in 2008 dollars) of
the total RBC transfusion-related costs. We found blood
acquisition and administration payments accounted for
50% to70% of total payments, but could not differentiate
acquisition and administration payments with certainty
in the claims data. Patient testing and administration and
monitoring of RBC transfusions and pretransfusion pro-
cesses were 24% to 36% of total costs. Managing acute
transfusion reactions and hemovigilance contributed to
0% to 2% of costs [21]. The type and level of detail avail-
able in the data as well as place of service (inpatient vs
outpatient setting) may explain some of the differences in
our estimates from those of Shandler et al. Moreover,
costs associated with blood acquisition and administra-
tion can vary according to the amount (units) and type
(eg, leukoreduced or irradiated) of blood.
Our study had several limitations. We followed patients
for mean 494.76 days, which was not long enough to
detect payments for iron overload. The analysis took a
conservative approach and excludes a number of poten-
tial resources that may increase the potential economic
burden. For example, a number of potential long-term
complications, including infectious diseases and iron
overload, were excluded and may result in an underesti-
mation of the overall economic burden of RBC transfu-
sions. In addition, long-term management of acute
complications such as medication costs and additional
outpatient management were not included in the ana-
lysis, all of which may result in underestimation of the
overall economic burden of RBC transfusions. Lastly,
the economic burden may be underestimated because
only hospitalizations related to specific complications
listed in Figure 2 were included. The analysis may be
potentially underestimating the economic burden by not
including hospitalization that may occur the day of or
day after a RBC transfusion because this may be a result
of the transfusion exacerbating a existing condition or
producing a new condition. Another limitation is the
potential to include acute renal failure patients in the
analysis. Utilizing a large number of dialysis claims over
a long period may result in a much healthier population
as a result of inclusion criteria. To minimize the poten-
tial for including acute renal failure or only including a
healthier population of ESRD patients on dialysis, the
analysis presented here utilizes specific codes that are
only utilized by ESRD patients on dialysis. Another
includes hospitalizations related to the specific acute
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design. We did not have information on patient race/
ethnicity. We were missing type of dialysis in about
one third of cases. We did not evaluate inpatient costs
because the inpatient claims data were based on
diagnosis-related group (DRG) codes and could not be
separated out into payment components. The focus of
this analysis was on the payer burden of RBC transfu-
sions and as a result of payments for inpatient hospital
admissions being capitated into DRG payments, there is
no ability to estimate the payer burden of inpatient-
administered RBC transfusions. The majority (about 85%)
of transfusions for dialysis patients occur in the inpatient
setting [22], and thus the economic burden of transfu-
sions is likely greatest in the inpatient setting, but of con-
cern to the inpatient hospital rather than the third party
payer, which is beyond the scope of this analysis. The
economic burden of inpatient transfusions is likely to be
similar to those for outpatient transfusions and the costs
associated with complications arising from outpatient
transfusions are also likely to be similar, if not greater
than outpatient transfusions as a result of patient severity
(as demonstrated by the patient being in the inpatient
setting). Future analyses should focus on the provider
cost burden of both outpatient and inpatient adminis-
tered RBC transfusions. Finally, patients in our sample
had either commercial insurance or Medicare plus
Medicare supplemental insurance as their primary cover-
age, and therefore, the results may not be generalizable
to patients who are uninsured, are covered only by Medi-
care, or have other types of insurance coverage.
Conclusion
This is the first study to examine payments for out-
patient RBC transfusions in a population of patients
undergoing chronic dialysis. Our study shows that pay-
ments for outpatient RBC transfusion episodes are pri-
marily driven by blood acquisition and administration
payments. Additionally, there are travel and other costs
to dialysis patients for RBC transfusion episodes and
increased risk for allosensitization; these could not be
estimated here, but are important costs associated with
RBC transfusions. While infrequent, transfusion compli-
cations increase payments substantially when they occur.
Better understanding of RBC transfusion episodes’ pay-
ments and costs to patient may help inform policy makers
when determining the appropriate reimbursement policy
for chronic dialysis patients.
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